Go to India PRwire homepage

Source: http://www.indiaprwire.com/pressrelease/medical/20171024521480.htm

DSM Sinochem Pharmaceuticals Initiates Patent Litigation Against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company Ltd.

DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has filed a lawsuit against CSPC Pharmaceutical Group Ltd., Inner Mongolia Changsheng Pharmaceutical Company Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company Ltd. for patent infringement.

Singapore, Singapore, October 24, 2017 /India PRwire/ -- DSM Sinochem Pharmaceuticals announced today that its wholly owned subsidiary, DSMSinochem Pharmaceuticals Netherlands B.V. filed a lawsuit against CSPCPharmaceutical Group Ltd., Inner Mongolia Changsheng PharmaceuticalCompany Ltd., and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) CompanyLtd. ("CSPC") for patent infringement in the District Court of The Hague, AfdelingHandel (commercial division), Netherlands, for patent infringement of the Dutchpart of European Patent Number 1,610,766 B1. This patent, which is owned byDSP, describes and claims amoxicillin trihydrate having a low free water contentand processes for the manufacture thereof. By its complaint, DSP seekscompensation for damages and a permanent injunction to prevent the infringingmanufacture, use, importation and sale of CSPC's amoxicillin activepharmaceutical ingredient, and/or any drug product that utilizes the activepharmaceutical, in the Netherlands.

"DSP has a world class intellectual property (IP) portfolio relating to ourinnovative, sustainable, and environmental friendly amoxicillin technology," saidKarl Rotthier, CEO at DSP. "After having previously filed patent litigation against Sinopharm Weiqida Pharmaceutical for patent infringement in India and the Netherlands in January 2017, DSP will continue to rigorously enforce its IPassets worldwide against any additional potential infringers as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins."

Notes to Editor

DSM Sinochem Pharmaceuticals

DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainableantibiotics, next-generation statins and anti-fungals. DSP develops, producesand sells intermediates, active pharmaceutical ingredients and drug products.Our employees worldwide work together to deliver cutting-edge genericssolutions that help to keep customers ahead of the competition.

Headquartered in Singapore, the group has manufacturing sites and sales officesin China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a50/50 Joint Venture of Royal DSM, a global science-based company active inhealth, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.

Forward-looking statements

This press release may contain forward-looking statements with respect to DSMSinochem Pharmaceuticals' (DSP) future (financial) performance and position. Such statements are based on current expectations, estimates and projections ofDSP and information currently available to the company. DSP cautions readersthat such statements involve certain risks and uncertainties that are difficult topredict and therefore it should be understood that many factors can cause actualperformance and position to differ materially from these statements. DSP has noobligation to update the statements contained in this press release, unlessrequired by law. The English language version of the press release is leading.

Please visit www.dsm-sinochem.com for more information or contact DSM Sinochem Pharmaceuticals Corporate Communications Alice Beijersbergen, Global Director Branding & Communications E-Mail: communications@dsm-sinochem.com

Journalists and Bloggers
Visit India PRwire for Journalists (http://www.indiaprwire.com/subscription/) for releases, photos, email alerts and customized feeds just for Media.

Source/Permanent Link: http://www.indiaprwire.com/pressrelease/medical/20171024521480.htm

© Copyright 2017. India PRwire (http://www.indiaprwire.com/) - A Dark Blue Technologies Company
India PRwire disclaims any content contained in press release. Use of our service is governed by our privacy policy and terms of service.